Boehringer Ingelheim Gains Access to Additional MorphoSys Technology
Product News Jul 11, 2008
MorphoSys AG has announced that Boehringer Ingelheim has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreement between the two companies.
As a result, Boehringer Ingelheim will have access to MorphoSys's RapMAT technology module alongside the existing installation of the Company's proprietary antibody library HuCAL GOLD at Boehringer Ingelheim's research site in Vienna, Austria.
Under the extended agreement, MorphoSys will receive annual user fees for the RapMAT technology and for access to its HuCAL platform. Financial details were not disclosed.
RapMAT, which stands for "rapid maturation", improves the options for identifying antibodies from the HuCAL libraries and reduces the time for generation of promising therapeutic lead molecules. The RapMAT technology is completely compatible with the HuCAL GOLD antibody library. MorphoSys believes that the use of RapMAT can greatly speed up antibody drug discovery, while widening the pool of drug candidates from which to choose.
Under the framework of the present five-year agreement, Boehringer Ingelheim has the option to receive multiple exclusive licenses on new therapeutic antibody programs. Now, the collaboration encompasses four active therapeutic antibody programs in various indications. Two new programs have been started recently and HuCAL-derived antibodies are currently being optimized at MorphoSys on behalf of Boehringer Ingelheim.